Literature DB >> 2177459

Frequent detection of hepatitis C virus US strain in Japanese hemophiliacs.

M Hijikata1, N Kato, S Mori, Y Ootsuyama, M Nakagawa, T Sugimura, S Ohkoshi, H Kojima, T Meguro, M Taki.   

Abstract

Hemophiliacs have been found to be at high risk of hepatitis. Hemophiliacs in Japan receive imported clotting factors as well as domestic ones. Recently we found that hepatitis C virus (HCV) could be classified into at least two types, HCV-US and HCV-J, depending on the nucleotide sequence. We analyzed the nucleotide sequences of virus RNAs from the plasma of patients with hemophilia A or B and found HCV-US in 3 of 4 Japanese hemophiliacs examined.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2177459      PMCID： PMC5918019          DOI： 10.1111/j.1349-7006.1990.tb02676.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN： 0910-5050


  10 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  Detection of serum hepatitis C virus RNA.

Authors:  S Kaneko; M Unoura; K Kobayashi; K Kuno; S Murakami; N Hattori
Journal:  Lancet       Date:  1990-04-21       Impact factor: 79.321

3.  Detection by PCR of hepatitis C virus in factor VIII concentrates.

Authors:  J A Garson; F E Preston; M Makris; P Tuke; C Ring; S J Machin; R S Tedder
Journal:  Lancet       Date:  1990-06-16       Impact factor: 79.321

4.  Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.

Authors:  J Bruix; J M Barrera; X Calvet; G Ercilla; J Costa; J M Sanchez-Tapias; M Ventura; M Vall; M Bruguera; C Bru
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

5.  Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma.

Authors:  M Colombo; G Kuo; Q L Choo; M F Donato; E Del Ninno; M A Tommasini; N Dioguardi; M Houghton
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

6.  Prevalence of antibody against non-A, non-B hepatitis virus in Japanese patients with hepatocellular carcinoma.

Authors:  S Ohkoshi; H Kojima; H Tawaraya; T Miyajima; T Kamimura; H Asakura; A Satoh; S Hirose; M Hijikata; N Kato
Journal:  Jpn J Cancer Res       Date:  1990 Jun-Jul

7.  Hepatitis C virus antibodies among risk groups in Spain.

Authors:  J I Esteban; R Esteban; L Viladomiu; J C López-Talavera; A González; J M Hernández; M Roget; V Vargas; J Genescà; M Buti
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

8.  Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients.

Authors:  M L Fletcher; J M Trowell; J Craske; K Pavier; C R Rizza
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-10

9.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

10.  Detection of hepatitis C virus RNA in sera and liver tissues of non-A, non-B hepatitis patients using the polymerase chain reaction.

Authors:  S Ohkoshi; N Kato; T Kinoshita; M Hijikata; Y Ohtsuyama; N Okazaki; H Ohkura; S Hirohashi; A Honma; T Ozaki
Journal:  Jpn J Cancer Res       Date:  1990-09
  10 in total
  2 in total

1.  Kinetic analysis of the nucleic acid chaperone activity of the hepatitis C virus core protein.

Authors:  Kamal kant Sharma; Pascal Didier; Jean Luc Darlix; Hugues de Rocquigny; Hayet Bensikaddour; Jean-Pierre Lavergne; François Pénin; Jean-Marc Lessinger; Yves Mély
Journal:  Nucleic Acids Res       Date:  2010-02-18       Impact factor: 16.971

2.  Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay.

Authors:  J Bukh; R H Purcell; R H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.